159981-13-2

Upstream product

• 848649-47-8 1-[2,3-O-bis(tert-butyldimethylsilyl)-5-O-(4,4'-dimethoxytrityl)-4-thio-β-D-ribofuranosyl]uracil 
• 149359-06-8 1-[5-(4,4'-dimethoxytrityl)-3-(t-butyldimethylsilyl)-4-thio-beta-D-ribofuranosyl]uracil 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 159981-09-6 N⁴-benzoyl-1-[5-O-(4,4'-dimethoxytrityl)-4-thio-β-D-ribofuranosyl]cytosine 

Downstream Products

• 172531-76-9 N⁴-benzoyl-1-[2-O-(tert-butyldimethylsilyl)-3-O-[(2-cyanoethyl)(N,N-diisopropylamino)phosphino]-5-O-(4,4'-dimethoxytrityl)-4-thio-β-D-ribofuranosyl]cytosine 
• 159981-11-0 N⁴-benzoyl-1-[2-O-(tert-butyldimethylsilyl)-5-O-(4,4'-dimethoxytrityl)-4-thio-β-D-ribofuranosyl]cytosine 

Relevant academic research and scientific papers

Improving RNA interference in mammalian cells by 4′-thio-modified small interfering RNA (siRNA): Effect on siRNA activity and nuclease stability when used in combination with 2′-O-alkyl modifications

A systematic structure-activity relationship study of 4′-thioribose containing small interfering RNAs (siRNAs) has led to the identification of highly potent and stable antisense constructs. To enable this optimization effort for both in vitro and in vivo

4’-THIONUCLEOSIDES AND OLIGOMERIC COMPOUNDS

The present invention provides modified oligomeric compounds and compositions of oligomeric compounds for use in the RNA interference pathway of gene modulation. The modified oligomeric compounds include siRNA and asRNA having at least one affinity modification.